PhaseI/II Study of neoadjuvant therapy with Carboplatin Paclitaxel plus Bevacizumab for stage II/IIIA(>T2) Non-squamous Non-Small-Cell Lung Cancer
- Conditions
- non-squamous non-small-cell lung cancer
- Registration Number
- JPRN-UMIN000007129
- Lead Sponsor
- 1-20-1, Handayama, higashi-ku, Hamamatsu, Shizuoka. Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Not provided
1) Pleural effusion, pericardial effusion and ascites to need treatment 2) Current or previous histoty of hemoptysis (2.5ml) due to NSCLC 3) Evidence of bleeding diathesis or hemoptysis 4) With great vessel invasion 5) Cavity in tumor 6) Patients with therapeutic anticoagulopathy (including Aspirin over 325mg/day) 7) Active concomitant malignancy 8) Severe complications a)Current or previous history of cerebrovascular disease b)Current or previous history of GI perforation c)Severe cardiac disease d)Patients with active lung disease such as interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, pulmonary fibrosis or drug-induced pneumonitis e)Traumatic fracture of unrecovery f) Uncontrollable peptic ulcer g)Uncontrollable hypertenson h)Uncontrollable infectious disease 9) History of severe allergic reaction with platinum drug ,chemotherapy drug or monoclonal antibody 10) Pregnant or breast-feeding females 11) Decision of ineligibility by a physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method STEP1 Safety STEP2 Overall Response Rate
- Secondary Outcome Measures
Name Time Method Pathological Complete Response Rate Complete Resection Rate Relapse Free Survival Rate(1year,2years) Overall Survival Rate(1year,2years) Adverse events Blood loss during Oparation /Operation Time